B细胞-话题@MedSci

#B细胞#

314篇内容 | 4746人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1273400, encodeId=091112e3400f0, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , objectType=article, longId=214902, objectId=ef3021490202, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef3021490202, replyNumber=0, likeNumber=50, createdTime=2021-07-29, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef3021490202, moduleTitle=Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef3021490202)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273399, encodeId=778e12e33993e, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, objectType=article, longId=212729, objectId=d16b212e29ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d16b212e29ab, replyNumber=0, likeNumber=85, createdTime=2021-06-16, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d16b212e29ab, moduleTitle=Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d16b212e29ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273398, encodeId=09ed12e3398f6, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, objectType=article, longId=212401, objectId=f48f21240133, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f48f21240133, replyNumber=0, likeNumber=59, createdTime=2021-06-08, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f48f21240133, moduleTitle=Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f48f21240133)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273397, encodeId=5c1612e339795, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, objectType=article, longId=211832, objectId=fc31211832f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fc31211832f6, replyNumber=0, likeNumber=73, createdTime=2021-05-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fc31211832f6, moduleTitle=Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fc31211832f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273396, encodeId=c67e12e339647, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, objectType=article, longId=211106, objectId=51f721110637, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=51f721110637, replyNumber=0, likeNumber=64, createdTime=2021-05-12, rootId=0, userName=智者为医08, userId=4dfa37, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=51f721110637, moduleTitle=NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51f721110637)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273395, encodeId=06f212e3395c2, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, objectType=article, longId=210737, objectId=56f3210e371b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=56f3210e371b, replyNumber=0, likeNumber=67, createdTime=2021-05-03, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=56f3210e371b, moduleTitle=Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=56f3210e371b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273394, encodeId=87d712e33942d, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响, objectType=article, longId=210613, objectId=3ae7210613fe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ae7210613fe, replyNumber=0, likeNumber=108, createdTime=2021-04-30, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ae7210613fe, moduleTitle=Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ae7210613fe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273393, encodeId=fd0a12e33933c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展, objectType=article, longId=210161, objectId=5e06210161dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5e06210161dd, replyNumber=0, likeNumber=81, createdTime=2021-04-20, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5e06210161dd, moduleTitle=Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5e06210161dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273392, encodeId=f62b12e339249, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, objectType=article, longId=208782, objectId=0413208e8273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0413208e8273, replyNumber=0, likeNumber=99, createdTime=2021-03-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0413208e8273, moduleTitle=J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0413208e8273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273391, encodeId=a6d112e33910c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, objectType=article, longId=208781, objectId=48ff208e81d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=48ff208e81d8, replyNumber=0, likeNumber=84, createdTime=2021-03-22, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48ff208e81d8, moduleTitle=Blood：血管内大B细胞淋巴瘤的遗传特征, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48ff208e81d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273389, encodeId=e0e812e338993, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, objectType=article, longId=207858, objectId=4adc20e8585b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4adc20e8585b, replyNumber=0, likeNumber=74, createdTime=2021-03-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4adc20e8585b, moduleTitle=JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4adc20e8585b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273388, encodeId=a65512e338803, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, objectType=article, longId=207857, objectId=663420e857ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=663420e857ae, replyNumber=0, likeNumber=70, createdTime=2021-03-05, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=663420e857ae, moduleTitle=JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=663420e857ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273390, encodeId=b57e12e339010, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, objectType=article, longId=207605, objectId=7f8820e605f3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7f8820e605f3, replyNumber=0, likeNumber=118, createdTime=2021-02-27, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7f8820e605f3, moduleTitle=J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7f8820e605f3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273387, encodeId=7f9b12e338713, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=207556, objectId=3aa220e556bc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3aa220e556bc, replyNumber=0, likeNumber=103, createdTime=2021-02-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3aa220e556bc, moduleTitle= Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3aa220e556bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273386, encodeId=c82d12e338634, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, objectType=article, longId=207011, objectId=dcad20e01104, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dcad20e01104, replyNumber=0, likeNumber=65, createdTime=2021-02-11, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dcad20e01104, moduleTitle=JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dcad20e01104)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273385, encodeId=b25512e33853a, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, objectType=article, longId=206908, objectId=2d6520690891, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d6520690891, replyNumber=0, likeNumber=78, createdTime=2021-02-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d6520690891, moduleTitle=美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d6520690891)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273384, encodeId=5bb812e338414, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, objectType=article, longId=206905, objectId=e68520690580, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e68520690580, replyNumber=0, likeNumber=73, createdTime=2021-02-09, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e68520690580, moduleTitle=Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e68520690580)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273383, encodeId=d15b12e33835c, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, objectType=article, longId=206779, objectId=c005206e79a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c005206e79a5, replyNumber=0, likeNumber=110, createdTime=2021-02-06, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c005206e79a5, moduleTitle=Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c005206e79a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273382, encodeId=669312e338227, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, objectType=article, longId=206207, objectId=df2920620e11, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2920620e11, replyNumber=0, likeNumber=63, createdTime=2021-01-26, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2920620e11, moduleTitle=YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=df2920620e11)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1273381, encodeId=de7c12e33817f, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, objectTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, objectType=article, longId=205595, objectId=b9f020559582, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b9f020559582, replyNumber=0, likeNumber=80, createdTime=2021-01-12, rootId=0, userName=xiaoyeshuang, userId=6eba113, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b9f020559582, moduleTitle=Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b9f020559582)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

B细胞

2020-05-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Med：同时靶向CD19和CD22的CAR T细胞治疗复发性或难治性B细胞恶性肿瘤：I期试验

2021-07-29

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：糖皮质激素对CAR-T细胞疗法治疗的大B细胞淋巴瘤患者预后的影响

2021-06-16

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Int J Clin Oncol：商品化 CAR T细胞治疗复发/难治性侵袭性B细胞淋巴瘤的疗效

2021-06-08

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Br J Cancer：弥散性大B细胞淋巴瘤DLBCL的新型风险分层预测模型

2021-05-27

智者为医08 (审核中...)

前往app查看评论内容

#B细胞#

NEJM：抗B细胞成熟抗原CAR-T细胞疗法bb2121治疗多发性骨髓瘤的效果

2021-05-12

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Lymphoma Myeloma Leuk：CAR-T疗法可用于治疗异体造血干细胞移植后复发/难治的B细胞急淋白血病患者

2021-05-03

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Science：新冠疫苗究竟管用多久？可能受年龄和组织中B细胞记忆的差异影响

2021-04-30

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Nat Commun：耗竭B细胞可逆转阿尔茨海默病的进展

2021-04-20

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Clin Oncol：新型双特异性抗体Glofitamab用于难治性侵袭性B细胞非霍奇金淋巴瘤的活性

2021-03-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：血管内大B细胞淋巴瘤的遗传特征

2021-03-22

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JAMA：Blinatumomab可提高首次复发的B细胞急性淋巴细胞白血病高危患儿无事件生存率

2021-03-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JAMA：Blinatumomab vs 化疗用于首次复发的B细胞急性淋巴细胞白血病儿童、青少年和年轻患者

2021-03-05

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

J Immunother Cancer：纳米胶囊化的利妥昔单抗在具有补体活性的人源化小鼠模型中介导对转移性B细胞淋巴瘤的优异细胞免疫

2021-02-27

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clinical Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-02-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

JCO：来那度胺联合R-CHOP治疗可延长未经治疗的弥漫性大B细胞淋巴瘤患者的生存期

2021-02-11

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

美国FDA宣布：全球第4款CAR-T细胞疗法获批上市，治疗复发性或难治性大B细胞淋巴瘤，安全性更高！

2021-02-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Lancet Haematol：MATRix–RICE方案联合自体HSCT治疗继发CNS浸润的弥漫大B细胞淋巴瘤的疗效显著

2021-02-09

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Blood：皮质醇用的越多，采用CAR T细胞疗法治疗的大B细胞淋巴瘤患者的预后越差！

2021-02-06

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

YESCARTA在日本获批用于治疗复发难治大B细胞淋巴瘤（DLBCL）

2021-01-26

xiaoyeshuang (审核中...)

前往app查看评论内容

#B细胞#

Clin Nutrition: 25（OH）D的生物利用度与弥漫性大B细胞淋巴瘤患者的临床结局相关

2021-01-12

科室
- - 订阅+
  - 更多科室
工具
服务